Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

October 6, 2025

Biodexa to Host Breakfast Symposium on

FAP Mechanisms and Chemoprevention Trial Issues

at CGA – IGC Conference on October 11, 2025

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, will host a breakfast symposium at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) annual meeting in St Louis, MO on October 9-11, 2025.

The symposium presentation, titled “FAP mechanisms and Chemoprevention Trial Issues” will be delivered by guest speaker Dr Patrick Lynch MD, Professor of Medicine (Rtd), Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center. After the presentation there will be an interactive panel discussion with panellists Sonia S. Kupfer MD, Professor of Medicine, University of Chicago and Paul E. Wise MD, Professor of Surgery, Washington University.

"We are honored to convene this distinguished panel at such a prestigious scientific forum," said Dr. Gary Shangold, Chief Medical Officer of Biodexa. "This symposium reflects the collaborative nature of our research approach and the significant scientific and clinical interest in advancing FAP treatment options. The insights shared will be invaluable as we continue to advance our Phase 3 Serenta trial and work toward potentially providing the first approved therapy for FAP patients."

The symposium takes place during a pivotal period for Biodexa's FAP program, as the company advances its Phase 3 Serenta trial of eRapa, a proprietary oral formulation of rapamycin. The trial represents a significant opportunity to address the substantial unmet medical need in FAP, where patients currently face limited options beyond surgical intervention. Several conference attendees are actively collaborating as clinical investigators in the ongoing Phase 3 study, highlighting the scientific interest in this therapeutic approach.

ENDS

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.

eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis.

Tolimidone is an orally delivered, potent and selective activator of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.

MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.

Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.

Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.